Equities analysts predict that Cardiovascular Systems Inc (NASDAQ:CSII) will report earnings of ($0.04) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Cardiovascular Systems’ earnings, with estimates ranging from ($0.06) to ($0.01). Cardiovascular Systems reported earnings per share of ($0.01) during the same quarter last year, which would suggest a negative year-over-year growth rate of 300%. The company is scheduled to issue its next earnings report on Wednesday, February 6th.

According to Zacks, analysts expect that Cardiovascular Systems will report full year earnings of ($0.09) per share for the current fiscal year, with EPS estimates ranging from ($0.13) to ($0.05). For the next fiscal year, analysts forecast that the business will post earnings of $0.06 per share, with EPS estimates ranging from $0.01 to $0.10. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that follow Cardiovascular Systems.

Cardiovascular Systems (NASDAQ:CSII) last posted its quarterly earnings data on Tuesday, October 30th. The medical device company reported ($0.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.03). Cardiovascular Systems had a return on equity of 0.62% and a net margin of 0.36%. The firm had revenue of $56.27 million during the quarter, compared to analyst estimates of $55.96 million.

Several research firms recently issued reports on CSII. BidaskClub upgraded Cardiovascular Systems from a “hold” rating to a “buy” rating in a report on Friday, August 10th. Lake Street Capital reiterated a “buy” rating and issued a $50.00 price objective on shares of Cardiovascular Systems in a report on Wednesday, August 1st. Zacks Investment Research cut Cardiovascular Systems from a “buy” rating to a “hold” rating in a report on Friday, August 3rd. Needham & Company LLC reiterated a “hold” rating on shares of Cardiovascular Systems in a report on Wednesday, October 31st. Finally, Stifel Nicolaus began coverage on Cardiovascular Systems in a report on Wednesday, August 22nd. They issued a “buy” rating and a $45.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $35.20.

CSII stock traded down $0.99 during trading on Monday, hitting $31.09. The stock had a trading volume of 320,833 shares, compared to its average volume of 365,854. The company has a current ratio of 4.54, a quick ratio of 4.03 and a debt-to-equity ratio of 0.16. Cardiovascular Systems has a twelve month low of $20.58 and a twelve month high of $40.00. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of 621.80 and a beta of 2.36.

In other news, General Counsel Alexander Rosenstein sold 1,344 shares of the business’s stock in a transaction that occurred on Friday, August 17th. The stock was sold at an average price of $37.56, for a total transaction of $50,480.64. Following the transaction, the general counsel now directly owns 49,469 shares in the company, valued at approximately $1,858,055.64. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Martha Goldberg Aronson bought 3,000 shares of the stock in a transaction dated Thursday, November 1st. The shares were bought at an average price of $28.72 per share, for a total transaction of $86,160.00. Following the completion of the acquisition, the director now owns 3,000 shares in the company, valued at $86,160. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 3,177 shares of company stock worth $119,274. 2.80% of the stock is currently owned by insiders.

Several institutional investors have recently modified their holdings of the company. Thomson Horstmann & Bryant Inc. boosted its holdings in shares of Cardiovascular Systems by 1.1% during the 3rd quarter. Thomson Horstmann & Bryant Inc. now owns 187,525 shares of the medical device company’s stock worth $7,339,000 after purchasing an additional 1,959 shares during the last quarter. Bank of Montreal Can boosted its holdings in shares of Cardiovascular Systems by 3.7% during the 3rd quarter. Bank of Montreal Can now owns 58,896 shares of the medical device company’s stock worth $2,305,000 after purchasing an additional 2,123 shares during the last quarter. Partner Investment Management L.P. boosted its holdings in shares of Cardiovascular Systems by 31.2% during the 2nd quarter. Partner Investment Management L.P. now owns 11,329 shares of the medical device company’s stock worth $366,000 after purchasing an additional 2,695 shares during the last quarter. Harvest Fund Management Co. Ltd acquired a new position in shares of Cardiovascular Systems during the 3rd quarter worth approximately $108,000. Finally, Wells Fargo & Company MN boosted its holdings in shares of Cardiovascular Systems by 7.0% during the 3rd quarter. Wells Fargo & Company MN now owns 52,045 shares of the medical device company’s stock worth $2,037,000 after purchasing an additional 3,406 shares during the last quarter. Institutional investors and hedge funds own 79.58% of the company’s stock.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.

Featured Story: How does a reverse stock split work?

Get a free copy of the Zacks research report on Cardiovascular Systems (CSII)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.